Cargando…

How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers

To evaluate China's current rifampin-resistant tuberculosis (RR-TB) screening strategy from stakeholders' perspectives, the perceptions, attitudes, and interests of 245 stakeholders from three eastern, central, and western China provinces on RR-TB screening strategies, were investigated th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hua, Qianhui, Xu, Hong, Chen, Xinyi, Pan, Junhang, Peng, Ying, Wang, Wei, Chen, Bin, Jiang, Jianmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651999/
https://www.ncbi.nlm.nih.gov/pubmed/34900894
http://dx.doi.org/10.3389/fpubh.2021.736632
_version_ 1784611497313304576
author Hua, Qianhui
Xu, Hong
Chen, Xinyi
Pan, Junhang
Peng, Ying
Wang, Wei
Chen, Bin
Jiang, Jianmin
author_facet Hua, Qianhui
Xu, Hong
Chen, Xinyi
Pan, Junhang
Peng, Ying
Wang, Wei
Chen, Bin
Jiang, Jianmin
author_sort Hua, Qianhui
collection PubMed
description To evaluate China's current rifampin-resistant tuberculosis (RR-TB) screening strategy from stakeholders' perspectives, the perceptions, attitudes, and interests of 245 stakeholders from three eastern, central, and western China provinces on RR-TB screening strategies, were investigated through stakeholder survey and interview. The attitudes toward three RR-TB screening strategies were statistically different: inclination to choose who to screen (Z = 98.477; P < 0.001), funding for rapid diagnostic technology screening either by reimbursed health insurance or directly subsidized financial assistance (Z = 4.142, P < 0.001), and respondents' attitude during RR-TB screening implementation levels (Z = 2.380, P = 0.017). In conclusion, RR-TB screening scope could be expanded by applying rapid diagnostic technologies. Provinces with different economic status could adjust their screening policies accordingly.
format Online
Article
Text
id pubmed-8651999
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86519992021-12-09 How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers Hua, Qianhui Xu, Hong Chen, Xinyi Pan, Junhang Peng, Ying Wang, Wei Chen, Bin Jiang, Jianmin Front Public Health Public Health To evaluate China's current rifampin-resistant tuberculosis (RR-TB) screening strategy from stakeholders' perspectives, the perceptions, attitudes, and interests of 245 stakeholders from three eastern, central, and western China provinces on RR-TB screening strategies, were investigated through stakeholder survey and interview. The attitudes toward three RR-TB screening strategies were statistically different: inclination to choose who to screen (Z = 98.477; P < 0.001), funding for rapid diagnostic technology screening either by reimbursed health insurance or directly subsidized financial assistance (Z = 4.142, P < 0.001), and respondents' attitude during RR-TB screening implementation levels (Z = 2.380, P = 0.017). In conclusion, RR-TB screening scope could be expanded by applying rapid diagnostic technologies. Provinces with different economic status could adjust their screening policies accordingly. Frontiers Media S.A. 2021-11-24 /pmc/articles/PMC8651999/ /pubmed/34900894 http://dx.doi.org/10.3389/fpubh.2021.736632 Text en Copyright © 2021 Hua, Xu, Chen, Pan, Peng, Wang, Chen and Jiang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Hua, Qianhui
Xu, Hong
Chen, Xinyi
Pan, Junhang
Peng, Ying
Wang, Wei
Chen, Bin
Jiang, Jianmin
How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers
title How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers
title_full How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers
title_fullStr How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers
title_full_unstemmed How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers
title_short How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers
title_sort how to effectively identify patients with rifampin-resistant tuberculosis in china: perspectives of stakeholders among service providers
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651999/
https://www.ncbi.nlm.nih.gov/pubmed/34900894
http://dx.doi.org/10.3389/fpubh.2021.736632
work_keys_str_mv AT huaqianhui howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders
AT xuhong howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders
AT chenxinyi howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders
AT panjunhang howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders
AT pengying howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders
AT wangwei howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders
AT chenbin howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders
AT jiangjianmin howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders